This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Drug Resistance in Pneumonia (DRIP) Score

    Predicts risk for community-acquired pneumonia due to drug-resistant pathogens.

    IMPORTANT

    We launched a COVID-19 Resource Center, including a critical review of recommended calcs. 

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with community acquired pneumonia.

    • Should be utilized only for bacterial causes of pneumonia.
    • False negatives can be seen in the following situations: MRSA or P. aeruginosa infection, severe COPD (requiring O₂ and steroids), IV drug use, psychiatric conditions, and homelessness.
    • False positives can be seen with S. pneumoniae and MSSA.
    • The DRIP validation study evaluated a broader set of risk factors than the HCAP definition.
    • The DRIP study reaffirmed that antibiotic use and hospitalization 60 days prior are major contributors to drug resistance, but did not find a strong association between severity of illness and drug resistance.
    • More predictive of drug resistant pathogens compared to HCAP and may have the potential to decrease antibiotic over-utilization in pneumonia.
    • Decreases use of unnecessary extended-spectrum antibiotics by 38% as compared with the HCAP definition (Webb 2019).
    • At a cut-off of ≥4 points, DRIP optimally differentiates high and low risk (PPV of 73.0, NPV 92.0, AUROC 0.88, accuracy of 87%), supporting its utility as a clinical decision tool to guide empiric antibiotic selection. Accuracy was defined as “percent of cases in which antibiotic spectrum (that would have been recommended based on DRIP classification) would have been appropriate for the recovered organism.”
    Major Risk Factors
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    Minor Risk Factors
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    Confirmed positive
    Suspected
    Unlikely
    Confirmed negative

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Brandon Webb

    From the Creator

    Why did you develop the DRIP Score? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?

    I developed the idea for the DRIP Score while working as a hospitalist before my infectious disease fellowship. I frequently admitted patients with pneumonia who met HCAP criteria, and yet few of them ended up requiring the vancomycin and broad-spectrum gram negative antibiotics we were giving.  

    When I started digging into the literature, I was surprised to find that use of these antibiotics had doubled in the last 10 years without an increase in rates of antibiotic-resistant bacteria! This led to the development of a score that would help clinicians more accurately decide which patients can safely be treated for community-acquired pneumonia.

    What pearls, pitfalls and/or tips do you have for users of the DRIP Score? Do you know of cases when it has been applied, interpreted, or used inappropriately?

    The DRIP Score was designed to improve specificity (less false positive identification of patients who don't have antibiotic resistant bugs), without sacrificing sensitivity (false negatives lead to inadequate antibiotic spectrum). No score is perfect, and DRIP is no exception. We are getting ready to report results of implementation of DRIP in nearly 2,000 patients and one thing we observed is that there are some patients, particularly with chronic pulmonary diseases, who have scores <4 but are colonized with MRSA or Pseudomonas. It is sometimes difficult to determine which of these patients truly have a true lower tract infection due these drug-resistant organisms from a sputum culture alone, however. Some clinicians at our institution are using a "clinical margin for error" approach - in critically-ill patients on vasopressors or mechanical ventilation, they consider using a threshold of 3 points or higher to initiate broad spectrum antibiotics.

    What recommendations do you have for doctors once they have applied the DRIP Score? Are there any adjustments or updates you would make to the score based on new data or practice changes?

    I have two recommendations for clinicians using DRIP: first, it is important to know what your local microbiology rates are. While many hospitals have low rates of MRSA and Pseudomonas as causes of community-onset pneumonia, DRIP may not work as well in some institutions and in some distinct patient populations such as transplant recipients with high multidrug-resistant organism (MDRO) prevalence.  

    My second recommendation is to consider deescalating antibiotics in patients with DRIP >4 who are started on broad spectrum regimens if no resistant organism is identified and the patient has achieved clinical stability. In our hospitals, we couple the DRIP score with the MRSA nasal PCR, which has a very strong NPV and allows clinicians to deescalate vancomycin earlier if negative. The PPV is not stellar, so even if it is positive but no MRSA is found in the blood or respiratory sample, vancomycin can often still be stopped.

    How do you use the DRIP Score in your own clinical practice? Can you give an example of a scenario in which you use it?

    At the 21 Intermountain healthcare hospitals, calculating DRIP is part of the order sets in our ED and hospitalist/intensivist bundles.

    Any other research in the pipeline that you’re particularly excited about?

    DRIP has now been implemented in several places around the country and we are looking forward to publication of several centers' experience using it, including our own.

    About the Creator

    Brandon Webb, MD, is a practicing infectious disease physician in the division of epidemiology and infectious diseases at Intermountain Healthcare in Utah. He has also served as an adjunct assistant professor at the University of Utah School of Medicine. Dr. Webb's research interests include bacterial pneumonia, antimicrobial stewardship, and transplant infectious diseases.

    To view Dr. Brandon Webb's publications, visit PubMed

    Content Contributors
    • John Dayton, MD
    About the Creator
    Dr. Brandon Webb
    Content Contributors
    • John Dayton, MD